Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.

Sci Rep · 2023 · PMC10029786 · PMID 36944687

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Difference of pseudotype virus neutralizing antibody (IC 50 ) reached statistical significance in BALF with highest titers in RBD-cCPE immunized animals, whereas in serum the IC 50 trended higher in RBD-cCPE animals and showed much less variability, but the differences did not reach statistical significance due to small group sizes.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.